Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stockholders Approve SELDI Divestiture to Bio-Rad

NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.
Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.
Ciphergen, which will now focus on its specialty diagnostic business, said it expects the deal to close before Nov. 1.
With the acquisition, Bio-Rad will be able to make and market Ciphergen’s surface enhanced laser desorption ionization technology, also known as SELDI, to the life sciences market for various proteomics applications.
Bio-Rad recently made two other purchases into the medical diagnostics market: The company bought Blackhawk Biosystems, a maker of infectious disease diagnostic products, for an undisclosed sum, and acquired Provalis’ medical diagnostic business for $3 million.
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.